Open an account

Rosetta Genomics

ROSGQ · OTC

Price unavailable right now.

No price history for this range.

About ROSGQ

Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.

Employees
86
Headquarters
REHOVOT
Listed
Feb 27, 2007
Sector
Health Care
Industry
Biotechnology
Website
rosettagenomics.com

ROSGQ key statistics

This section is temporarily unavailable. Refresh to try again.

ROSGQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.6% on average.

  1. Q2 FY13: reported -$8.16 per share against an estimate of -$3.58
  2. Q4 FY13: reported -$7.92 per share against an estimate of -$6.12
  3. Q2 FY14: reported -$7.92 per share against an estimate of -$8.28
  4. Q4 FY15: reported -$1.68 per share against an estimate of -$2.47
  5. Q1 FY16: reported -$2.16 per share against an estimate of -$1.98
  6. Q2 FY16: reported -$1.92 per share against an estimate of -$2.14
  7. Q3 FY16: reported -$2.28 per share against an estimate of -$2.04
  8. Q4 FY16: reported -$2.73 per share against an estimate of -$1.42

Similar companies

Companies in the same industry as Rosetta Genomics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.